Tag: Viral suppression

According to the Centers for Disease Control and Prevention (CDC), suppressive therapy with antiviral drugs can reduce the frequency of genital herpes recurrences by 70–80% for those with frequent outbreaks. This strategy, particularly using daily valacyclovir suppression, is a cornerstone for managing chronic viral infections like herpes simplex virus (HSV).

For antiretroviral-naive HIV-1 patients, tenofovir (TDF) containing regimens demonstrated virologic suppression rates of approximately 90% at 48 weeks in clinical trials. This impressive efficacy highlights a key aspect of the success rate of tenofovir in managing viral infections, though specific outcomes vary based on the treated condition, patient adherence, and the specific tenofovir formulation used.